

Applicants: Yuti Chernajovsky, et al.
U.S. Serial No.: 09/285,531
Filed: April 2, 1999
Page 2

In the claims:

Please amend claims 20-23, 27 and 34-37 as follows:

E¹ 20. (Thrice amended) A method of treating a tumor necrosis factor-related disease in a subject in need thereof comprising administering to the subject a TNF-inhibiting amount of a receptor molecule according to Claim 1.

E² 21. (Twice Amended) The method of Claim 20, wherein the tumor necrosis factor-related disease is selected from the group consisting of: an autoimmune disease, an inflammatory bowel disease, a bacterial infection, a viral infection, a parasitic infection, a malignancy, and a neurodegenerative disease.

22. (Twice Amended) The method of Claim 21, wherein the tumor necrosis factor-related disease is selected from the group consisting of: rheumatoid arthritis, septic shock, cerebral malaria, inflammatory bowel disease, multiple sclerosis, allograft rejection, host versus graft disease, neoplastic pathology and endotoxemic response.

23. (Twice Amended) The method of Claim 20, wherein the tumor necrosis factor-related disease is rheumatoid arthritis.

E³ 27. (Twice Amended) The receptor molecule of Claim 1, wherein the tumor necrosis factor receptors are of human origin and the polypeptide linker is a polyglycine linker sequence.